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HEALTH RISKS OF VERY LOW CHOLESTEROL
ABSTRACT

Menachem Nagar

Cholesterol is a molecule central to all human physiological processes at systemic as
well as cellular levels. Cholesterol, combined with Apolipoprotein B as low-density lipoprotein
(LDL) has been the focus of scientific research because the molecule has been proven to play a
role in the development of cardiovascular disease, a disease of pandemic proportions.
Considerable scientific and medical attention has been devoted to identifying the role and
management of high levels of total serum cholesterol in order to address this global health
burden, creating large scale awareness regarding lowering cholesterol concentration in
circulation. However, the same molecule, combined into various lipoprotein moieties, is also
involved in ‘normal’ physiological processes. In this review, an attempt has been made to
elucidate some of the physiological events at the other end of the spectrum, when serum
cholesterol levels are lower than normal. These health risks may need to be managed by going
against the grain and actually raising serum cholesterol levels. Hypocholesterolemia is perhaps
as much of a health risk as is hypercholesterolemia. These phenomena emphasize the fact that
where cholesterol is concerned, maintenance of optimal systemic levels of cholesterol is more
crucial than going towards either end of the cholesterol scale.
INTRODUCTION

Cholesterol has been in the center of many debates concerning its role in the
human metabolism. Cholesterol is considered as the main culprit behind modern
lifestyle diseases like atherosclerosis, which leads to cardiac arrest, obesity and
metabolic syndrome. Although implicated as a causative agent of all of the above,
cholesterol is also an important component of cellular membranes and is a mediator of
several cellular processes. Cellular membranes owe their fluidity to the presence of
cholesterol and lack of cholesterol is likely to have an impact on several physiological
processes. Cholesterol is an important precursor for synthesis of steroid sex hormones
(Payne and Hales 2004) as well as vitamin D (Lehmann et al. 2000). Cholesterol is an
important constituent of cell membranes and, being an amphipathic molecule, it
interacts with both lipids in the plane of the membrane bi-layer, as well as with water
and other electrolytic substances owing to the presence of an –OH group. Cholesterol
is thought to play an important role in maintaining membrane fluidity as well as
participate in transient membrane specializations called membrane microdomains or
‘rafts’ (Sharma et al. 2004).
The role of LDL in the development of cardiovascular disease (CVD), when
present in excess in human circulation, has been discussed at length (Stein 2009). The
consensus is that very high levels of serum LDL-cholesterol and triglycerides are the
causative factors of atherosclerotic plaques, which can eventually cause blockage of
cardiac arteries leading to a heart attack. There have been extensive studies on the
interrelationships between diet, obesity, serum cholesterol levels and CVD as well as
other co-morbidities like diabetes mellitus (Daniels et al. 2009), leading to the
formulation of a general assumption that one must slay the cholesterol beast in order to
live a disease-free life. However, cholesterol is also an essential component of
biological tissues and is also specifically required for several cellular processes.
Therefore, the issue that begs consideration here is “How low can one go with
cholesterol?” Given the importance of having an optimal amount of cholesterol present
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in the human system, it is likely that extremely low levels of cholesterol are likely to
bring in another set of health morbidities and risk. This review attempts to understand
health risks at the other end of the cholesterol range by looking at cholesterol
deficiency disorders. Physiological deficits in cholesterol levels can result from a
variety of causes and the effects of these deficiencies on various health parameters are
discussed in this review.

CHOLESTEROL METABOLISM

Cholesterol can be synthesized by all tissues in the human body, barring
enucleated erythrocytes. In addition to synthesis of cholesterol from acetate,
cholesterol is also absorbed from ingested food in the form of chylomicrons.
Chylomicrons are a class of lipoproteins that are produced by intestinal mucosal cells,
the principal component of which is a small protein apoB-48, produced by alternative
splicing of mRNA from the apoB gene. Chylomicrons are generated in the intestinal
cells after the absorption of free fatty acids and cholesterol and are secreted by the
intestinal cells into the lacteals and are redistributed to other organs and peripheral
tissues. Chylomicrons are capable of exchanging apolipoproteins with high-density
lipoproteins (HDL) to generate mature chylomicrons. Cholesterol from peripheral
tissues is exported in the form of HDL, which is brought to the liver via the vascular
system. HDL-associated cholesterol and phospholipids are degraded in the liver.
Cholesterol breakdown products are excreted in bile as bile salts, which, after storage
in the gall bladder, are secreted into the digestive system. Bile salts help in
emulsification of dietary fats until they are absorbed in the small intestine.
The liver is also the site of cholesterol synthesis and hepatic cholesterol is
secreted into the vascular system in the form of very low-density lipoproteins (VLDL).
In the plasma, VLDLs coalesce to form low-density lipoprotein (LDL) particles.
Cholesterol deficiencies can be classified into
a) Inborn errors in cholesterol synthesis or apolipoprotein synthesis
b) Clinically observed hypocholesterolemia of undetermined origin such as
in HIV-positive patients (Miguez et al. 2010; Shor-Posner et al. 1993)
c) Cholesterol deficiency induced by surgery and critical illness

THE ROLE OF HDL IN CARDIOVASCULAR DISEASE

Cholesterol is present in serum in three forms: very low-density lipoprotein
(VLDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL), with
each form serving a distinct physiological function. Very low-density lipoprotein is the
form that is created by processing of HDL and LDL by the liver into smaller particles
meant for excretion. LDL has been implicated as a causative factor principally in
atherosclerosis especially when plasma concentrations of LDL are high (Daniels et al.
2009). HDL, on the other hand, functions to transport cholesterol from peripheral
tissues to the liver for degradation (Podrez 2010). HDL is chiefly composed of
apolipoproteins A I and II (apoAI and apoAII) with apolipoproteins C, D, E, M and
A-IV(apoC, apoD, apoE, apoM, apoA-IV) and other enzymes forming the protein
components of the particles. Cholesterol is the main lipid component but other
phospholipids as well as free fatty acids have also been reported to be included in
HDL.
A sum total of 75 proteins have been found to be included in HDL in proteomic
studies. These findings suggest that HDL may exist in several distinct forms engaged
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in several functions apart from transporting cholesterol to the liver (reviewed in
Podrez 2010). In fact, HDL plays a prominent role as an anti-oxidant molecule by
preventing oxidation of LDL and acting as a ‘sink’ for oxidized lipids from LDL
(Podrez 2010; Terasaka et al. 2007). The role of HDL as an antioxidant is thought to
help in preventing the formation of dysfunctional LDL molecules that may play a role
in initiating atherosclerotic plaques (Terasaka et al. 2007). HDL is thought to have a
cardioprotective role and help prevent cardiovascular disease. Low HDL is considered
as a positive predictor for cardiovascular disease (Schaefer et al. 2010). Patients with
mutated apoA-I show normal levels of LDL and serum triglycerides and yet are at
greater risk of developing coronary heart disease (Schaefer et al. 2010).
The link between circulating levels of HDL and coronary heart disease has
been demonstrated by other researchers as well. In a 16-year follow-up study with
3,026 patients, treatment with bezafibrate reduced the risk of coronary heart disease
and death by myocardial infarction by 22% as compared with patients who had been
prescribed a placebo (Goldenberg et al. 2009). In this study, patients who showed a
greater increase in serum HDL levels in response to bezafibrate were at lesser risk for
developing coronary heart disease. The study vindicates the role of HDL in preventing
atherosclerosis as well as coronary heart disease. In a Finnish population study of 148
people who presented with low HDL levels, a reduction in HDL particle size was
positively correlated with increased carotid intima-media thickness (Watanabe et al.
2006). Increase in the thickness of carotid intima and media, as assessed by
ultrasonography, is considered as a reliable marker for atherosclerosis. In this study,
people with low serum concentrations of HDL also showed a significant reduction in
the HDL particle size and were consequently deemed to be at greater risk for
development of coronary heart disease.
Given the diversity of proteins and lipids associated with HDL in addition to
cholesterol (Podrez 2010), heterogeneity in size and diversity of functions of HDL is
to be expected. In a study that sought to understand the relationship between HDL
particle size and coronary heart disease, Arsenault and colleagues found that smaller
HDL particle size (which can possibly be attributed to deficiencies in proteins as well
as associated cholesterol and other lipids) (Arsenault et al. 2009) was positively
correlated with increased risk for coronary heart disease. Patients with smaller sized
HDL particles also had greater co-incidence of other unfavorable cardiometabolic
factors like elevated waist circumference and higher systolic blood pressure and
elevated serum triglyceride levels. The study does indicate that predominance of HDL
and large sized HDL particles are indicators of cardiovascular risk, however; analysis
of the specific contribution of serum cholesterol was not carried out in this context.
The predominant question that arises from the previous discussion is whether
HDL particle size is regulated by cholesterol levels or not. HDL particle size analysis
was undertaken in a study of people who were heterozygous for Tangier disease (TD)
(Brousseau et al. 2000). Tangier disease is characterized by the presence of orange
tonsils, very low levels of HDL and enlarged spleen and liver. The essential mutation
in Tangier disease is one that causes a dysfunctional ATP-binding cassette transporter
protein ABC1 on chromosomes 9q31. This transporter protein regulates the efflux of
cholesterol from peripheral tissues and allows it to complex with apoA-I and apoA-II
to form HDL. In patients heterozygous for Tangier disease mutation, HDL particle
size was significantly smaller than that seen in controls. Efflux of cholesterol from TD-

Health Risks of Very Low Cholesterol

29

heterozygote cells was reduced by 50 % to that of control cells and this reduction in
serum cholesterol correlated positively with serum HDL concentration as well as
HDL particle size (Brousseau et al. 2000). Cholesterol efflux may also influence the
HDL-subtype distribution in Tangier disease heterozygotes (Asztalos et al. 2001).
HDL subpopulations can be characterized on the basis of size as well as the
predominant apolipoproteins associated with them. In a study of people heterozygous
for Tangier disease as confirmed by low HDL levels, the prevalence of large alpha1,
pre-alpha1, alpha 2 and pre-alpha2 particles was significantly lower as compared to
healthy control subjects. The loss of these specific HDL subpopulations may be the
result of reduced cholesterol efflux mediated by the Tangier mutation in the ABC-1
gene (Asztalos et al. 2001). Concurrently, the incidence of coronary heart disease was
also found to be greater by 60%, in the heterozygote group as compared to unaffected
healthy subjects. Therefore, cholesterol deficiency is likely to influence the particle size
as well as the specific nature of HDL particles; it is likely that very low levels of
cholesterol in the serum may actually contribute to increasing the risk of coronary
heart disease. Although this sounds contradictory to conventional wisdom that
cholesterol in the form of LDL IS the ‘seed’ molecule for formation of atherosclerotic
lesions, the lack of HDL particles of appropriate size and functional properties is a
serious concern for people with very low levels of serum cholesterol.

CHOLESTEROL AND NUTRITION
Lipoproteins are involved in the transport of vitamin E from the digestive
system as well as from the liver to the peripheral tissues. Vitamin E or alphatocopherol is known to bind to HDL, specifically HDL-3 (Goti et al. 1998). HDL-3
bound tocopherol can be taken up by hepatocytes (in in vitro studies) and is secreted
out in the form of LDL by hepatocytes. Thus both metabolic forms of cholesterol in
the form of lipoproteins are involved in the systemic transport of vitamin E.
Cholesterol is known to participate in transient membrane specializations
termed as membrane microdomains, along with sphingolipids (Sharma et al. 2002).
These microdomains are formed laterally in the plane of the plasma membrane and are
especially important for the endocytosis of the folate receptor. Depletion of cellular
cholesterol, in in vitro systems has been shown to alter the endocytic pathway
(Sabharanjak et al. 2002), recycling time as well as intracellular endosomal destination
of the folate receptor (Sabharanjak and Mayor 2004). The overall efficiency of
accumulating folic acid in the cytoplasm is also reduced. Although it is unclear whether
physiological depletion of cholesterol either by suppression of synthesis or by reduced
dietary intake results in similar disruption of microdomains, the role of cholesterol in
uptake of water-soluble vitamins is also important.

DEFICIENCIES IN CHOLESTEROL BIOSYNTHESIS

Cholesterol in circulation can be derived from dietary components as well as
from de novo synthesis. Cholesterol is synthesized from hydroxymethylglutaryl co-A
(HMGco-A) in a series of steps with intermediates like squalene, lanosterol and
lathosterol. Cholesterol thus synthesized may also get converted into steroid hormones
like testosterone. Incidentally, low testosterone levels in men are also correlated with
increased risk of coronary heart disease and show a positive correlation with low levels
of HDL as well (Nettleship et al. 2009).
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In the biosynthesis of cholesterol, lanosterol is converted via seven steps to
lathosterol, which in turn in converted into 7-dehydrocholesterol by the action of
lathosterol-5-desaturase. Mutations in this enzyme lead to the accumulation of
lathosterol instead of cholesterol, a defect known as lathosterolosis. This defect has
been replicated in a mouse model for lathosterolosis. Likewise, the final step in
biosynthesis is the conversion of 7-dehydrocholesterol to cholesterol catalyzed by 7dehydrocholesterol reductase. A genetic mutation of this enzyme has been described as
the Smith-Lemli-Opitz syndrome (SLOS), which is characterized by severe
developmental abnormalities including mental aberrations (Gondre-Lewis et al. 2006).
Both these defects have been established in mouse models described by Y Peng
Loh and colleagues (Gondre-Lewis et al. 2006). In order to examine the effect of
abnormal sterol accumulation in membrane trafficking events, these scientists
characterized and quantified the occurrence of dense core secretory granules in
exocrine pancreatic tissue as well as neuroendocrine cells. In Sc5d-/- as well as Dhcr7-/mice, the number of secretory granules in pancreatic tissues was significantly lower
than that found in wild type or heterozygous mice. (Gondre-Lewis et al. 2006).
Additionally, the fission of dense core granules from the endoplasmic reticulum was
seen to be impaired in Dhcr7-/- mice, suggesting that lack of cholesterol had interfered
with formation of dense core granules at the Golgi. The proportion of immature
granules lacking the dense core was higher in the mutant homozygous mice as
compared to wild type mice. The accumulation of sterols other than cholesterol is
likely to hinder secretory processes. Although alpha-amylase was produced by normal
as well as homozygous mutant mice with both genetic defects, the enzyme was found
to be constitutively secreted in Dhcr7-/- mice, indicating that cholesterol in the granule
membrane as well as plasma membrane of pancreatic acinar cells is essential for
regulated secretion of digestive enzymes.
This study highlights the importance of having the right sterol in the right
cellular membranes. The mutant phenotype can be rescued by culturing cells from
these mice in normal LDL-containing serum (or by dietary supplementation in the live
animal), which vindicates the requirements of cholesterol in cellular membranes in
regulated membrane trafficking events.
Although the lipoprotein measurements in the mouse models have not been
reported in this study, HDL deficiency has been shown to be associated with SLOS in
children (Behulova et al. 2000). In this study, serum lipoprotein levels were recorded
in children suffering from SLOS, ranging from five days to seven years of age. Total
cholesterol levels were certainly depressed in these children as compared to normal
children but the authors note that the severest symptoms of SLOS were exhibited by
children with significantly depressed levels of HDL and HDL-bound cholesterol
(Behulova et al. 2000). Developmental abnormalities resulting from cholesterol
deficiency in this syndrome usually mean that children are not able to attain adulthood.
Heterozygous individuals show normal development owing to the presence of the
normal DHCR7 allele.

HYPERCHOLESTEROLEMIA AND SURGICAL AND CRITICALLY ILL
PATIENTS

In order to understand hypocholesterolemia, ‘normal’ levels of cholesterol have
to be defined. From studies of primates as well as ‘primitive’ humans like tribals, the
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optimal serum concentrations of total cholesterol was found to be 3.0 to 4.0 mmol/l.
Plasma total cholesterol levels ranging from 2.6 to 3.5 mmol/l have been considered as
low cholesterol levels in certain conditions (Vyroubal et al. 2008). However, these
values show a large overlapping range. In another study, the plasma cholesterol
concentration of patients undergoing hepatectomy was judged relative to their own
total cholesterol estimations before and after surgery (Giovannini et al. 1999). This
study shows that patients whose total plasma cholesterol levels were reduced to 55% of
the pre-operative values were judged as hypocholesterolemic and tended to develop
fatal health complications.
In some papers, patients with cholesterol levels <150 mg/dl have been
considered as being hypocholesterolemic (Miguez et al. 2010; Shor-Posner et al. 1993).
Cholesterol levels may become a useful diagnostic tool in the prognosis of
critically ill or surgical patients in the recovery period. Dunham and colleagues have
demonstrated an association between the hypocholesterolemic state and likelihood of
recovery in patients who have suffered severe injuries (Dunham et al. 2003). In their
study of 28 patients maintained on ventilator support, reduction in plasma cholesterol
levels was observed in the beginning of the convalescence period. Those patients for
whom cholesterol levels rose to the normal population average were able to recover
from the trauma and were at reduced risk for sepsis. In contrast, patients with
persistent hypocholesterolemia tended to develop secondary infections as well as organ
failure and metabolic dysfunction (Dunham et al. 2003). The association between
development of sepsis and reduced levels of cholesterol is attributed to the fact that
lipoprotein complexes are able to sequester bacterial lipopolysaccharides and prevent
toxicemia. Reduced levels of serum lipoproteins are therefore a predisposition towards
developing secondary bacterial infections.
Although this study is limited by the number of patients included in the study
as well as lack of differentiation between the kinds of lipoproteins (LDL or HDL)
involved, it is nonetheless an eye-opener for critical care procedures. A study with
animal models wherein sepsis had been induced by irradiation showed that HDL is
persistently lowered (for up to 10 days in the recovery period) in individuals who
developed sepsis following irradiation (Parra et al. 2007).
Hypocholesterolemia has been shown to be associated with postoperative
surgical complications as well. Leardi and colleagues have noted that following
invasive abdominal surgery, patients whose total cholesterol levels fell below 105 mg/dl
showed the highest incidence of sepsis (Leardi et al. 2000) in the recovery period.
Likewise, an association between lowered cholesterol levels and increased incidence of
sepsis and multiple organ failure has been reported by Giovannini et. al in a
comparative study of 135 surgical patients (Giovannini et al. 1999).
Taken together, these studies indicate that cholesterol homeostasis (balance) in
circulation is important for recovery from accidents as well as planned interventions
like surgery. Hence, hypocholesterolemia is a risk factor to be considered, perhaps,
before opting for invasive surgical procedures. This fact is likely to be most relevant
for people bearing known cholesterol metabolism disorders as well as for people
undergoing statin-based therapy to reduce cholesterol levels.
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CHOLESTEROL AND INFECTION
Cholesterol-sequestering lipoproteins are also likely to play a protective role
against infection in non-traumatized and non-surgical patients as well. The
sequestration of bacterial lipopolysaccharides (LPS) by LDL to reduce the
inflammatory response that is launched to counter LPS has been well characterized.
Experiments conducted with knock-out mice that lacked the LDL-receptor gene
showed total susceptibility towards septicemia and eventually died (Lanza-Jacoby et
al. 2003). This research suggests that LDL bound to bacterial LPS may be
endocytosed by cells bearing the LDL-receptor in order to inactivate this exotoxin.
In humans, Staphylococcus aureus is a bacterium that not only colonizes and
persists in the system in the form of biofilms but can also aggressively invade tissues
leading to system-wide sepsis. In fact, resistance of Staphylococcus aureus to many
antibiotics is a major health issue that results in nosocomial (resulting from a hospital
stay) infections (reviewed in Falcone et al. 2009). In the colonized state, when the
biofilm reaches a certain bacterial population size, an operon termed as agr is switched
on, triggering an invasive infectious response. Peterson and others have shown that
apolipoprotein B is a natural antagonist of the agr-mediated aggressive infection. ApoB
binds to an auto-inducing cyclic thiolactone peptide (AIP) and prevents the binding of
this protein to its receptor AgrC (Peterson et al. 2008). ApoB is also capable of
sequestering other forms AIP2-4 and therefore confers protection against S. aureus
infections. It is therefore likely that extremely low levels of LDL-cholesterol may
actually result in loss of protection from S. aureus infections. This is especially a risk
factor for people bearing implants such as pacemakers since S. aureus biofilms are often
associated with such implants.
LDL is a defensive barrier against other bacterial toxins like the Vibrio vulnificus
cytolysin (Park et al. 2005). LDL has been shown to bind and inactivate the endotoxin
by causing oligomerization of the toxin. An important feature of this interaction is that
this is a dose–dependent inactivation mechanism (Park et al. 2005). Therefore, in
hypocholesterolemic conditions, the reduced availability of LDL is likely to enhance
the cytotoxicity of bacterial toxins, a factor that may lead to rapid onset of sepsis.
Typically, in trauma patients, when total serum cholesterol levels fall to 50% of the
normal population average levels, the risk of sepsis as well as multiple organ failure is
high (Vyroubal et al. 2008). These interdependencies highlight the fact that an
‘optimal’ cholesterol balance is required and low levels of cholesterol are just as
detrimental to health as elevated levels of cholesterol.

CHOLESTEROL IN MENTAL HEALTH
Cholesterol, being a membrane component, plays significant roles in neural
functions as well. In fact, cholesterol is a major component of the myelin sheath that
covers axons of brain neurons (reviewed in Fantini and Barrantes 2009) and is
thought to modulate neurotransmitter release and binding to neurotransmitter
receptors and therefore downstream events. A major neurotransmitter, serotonin, is
important for the emotional well-being of humans and serotonin deficiencies are
responsible for depression as well as aggression and suicide.
An association between serum cholesterol levels and serotonin has been
established in several studies. People whose serum cholesterol levels are low also tend
to have lower levels of serotonin in circulation (Steegmans et al. 1996). In a recent
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study, it was seen that low serum cholesterol correlated with serotonin turnover in
men. No such conclusive relationship could be demonstrated for women (Markianos et
al. 2010). These scientists have postulated that lowered serotonin levels could be
responsible for aggressive and violent behavior in men as a response to the
evolutionary need to hunt and acquire food.
In a retrospective analysis of familial and personal suicide attempts, Bocchetta
and colleagues have proposed a link between low cholesterol and suicidal behavior. A
total of 783 patients who were undergoing lithium treatment were analyzed for
reported personal or familial (first-order relative) suicide attempts. Based on one-time
cholesterol measurements, the researchers found that lower levels of serum cholesterol
in men were associated with attempted or completed suicide (Bocchetta et al. 2001),
suggesting a neuromodulatory role for cholesterol.
In another study with panic disorder patients, the serum cholesterol levels in
patients who attempted suicide were found to be lower than panic disorder patients
who had not attempted suicide as well as normal control subjects. The mean total
cholesterol levels as well as LDL levels were lower in panic disorder patients who had
attempted suicide (Ozer et al. 2004). The study is hampered by limited sample size as
well as a large age range of subjects. Extensive analyses will be required to further
understand the association between low cholesterol and suicidal behavior.
In a study of 42 people who attempted suicide, a positive correlation was found
between low serum cholesterol and low 5-hydroxyindoleacetic acid (5-HIAA) in the
cerebrospinal fluid (Asellus et al. 2010). These patients were not under the influence of
any other drug or therapy and had attempted suicide. The link between low serum
cholesterol and depressed serotonergic responses has been suggested to explain these
results. Although the cohort size was small with 42 individuals included, it is logically
and practically difficult to add to these numbers of people who attempted suicide but
missed the bus. Nonetheless, the work does show a correlation between low serum
cholesterol and attenuated serotonergic response systems, which, perhaps is
responsible for reckless suicidal behavior.
At the cellular level, a drastic reduction in the level of cholesterol is likely to
affect the physiology of serotonin receptors (Paila et al. 2008). Paila and colleagues
have used an inhibitor AY9944 in Chinese Hamster ovary fibroblast (CHO) cells to
create a cellular model of the Smith-Lemli-Opitz syndrome. AY9944 inhibits the
terminal step in the synthesis of cholesterol. In this model, signaling via the serotonin
1A (5-HT1A) receptor was found to be reduced (Paila et al. 2008). The attenuation of
signaling via this receptor was not explained by reduction in receptor expression or
delivery to the plasma membrane. However, signaling via plasma membrane-resident
5-HT1A was reduced in the absence of cholesterol. Although these cells have
abundant 7-dehydrocholesterol and 8-dehydrocholesterol, these sterols were not able
to interact with 5-HT1A in the same manner as cholesterol and facilitate signaling via
receptor-associated G-proteins (Paila et al. 2008). The overall membrane organization
as measured by the fluidity of a non-specific fluorescent probe was unaffected in
normal as well as SLOS cells used in this study. These results argue for a role of
cholesterol in modulating serotonin signaling, albeit in a cell system that is nonneuronal.
In hippocampal tissue, oxidation of cholesterol reduced the binding of agonist
as well as antagonist ligands to 5-HT1A receptor (Pucadyil et al. 2005). These results
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indicate a physical interaction between cholesterol in the plane of the membrane and
the neurotransmitter receptor. Taken together, these results suggest a mechanism for
impairment of serotonin receptor dysfunction in situations of low cholesterol
availability. Attenuated serotonin metabolism is a hallmark of depression and reduced
availability of cholesterol may be a contributory factor.
Cholesterol deficiencies are likely to manifest as changes in behavioral patterns
as well. In a one-year follow-up of patients with unipolar or bipolar disorder, a positive
correlation between low serum cholesterol and recurrence of manic episodes was noted
(Fiedorowicz et al. 2010). The patients were assessed for serum cholesterol along with
other parameters, as well as development of psychotic episodes. Patients with unipolar
disorder were not affected but those with bipolar disorder experienced manic episodes
in the year of follow-up. Depression was not seen in both kinds of patients. Although
the difference in mean cholesterol levels of both groups of patients was slim, the
persistent deficiency of cholesterol is likely to be influential in neurological responses
and behavior. In this study, the prevalence of different fractions of cholesterol
throughout the follow-up period was not monitored and perhaps better assessment of
the cholesterol status of the patient at the time of occurrence of psychotic / manic
events will shed more light on the role of cholesterol (Fiedorowicz et al. 2010). It
would be interesting to know whether a sudden and transient reduction in serum
cholesterol levels is a trigger or indicator of manic behavior. Since depressive
symptoms were not associated with hypocholesterolemia, the study points to other
neuromodulatory roles of cholesterol which remain to be investigated.
Dietary intake of cholesterol was shown to reduce dissociative behavior and
aggression in a primate study (Kaplan et al. 1994). Cynomolgus monkeys were fed
high-fat diets that were specifically low or high in cholesterol. Monkeys who received a
low cholesterol diet showed aggressive behavior and tended to be socially alienated.
Serum cholesterol levels may play an important role in addiction as well as deaddiction from cocaine. In a study of thirty-eight cocaine abusers in hospital-based
rehabilitation, it was seen that serum HDL levels were depressed in these patients,
even in the recovery phase. Serum LDL, HDL cholesterol as well as neuroendocrine
responses were assessed two weeks after discontinuation of cocaine abuse. Serum
HDL cholesterol was reduced in all patients. The reduction in HDL also correlated
with greater experience of a ‘high’ feeling and euphoria when the same patients were
challenged with m-chlorophenylpiperazine (m-CPP). These responses are known to be
attributed to altered serotonergic neuronal transmission. In agreement with prior
studies, reduced HDL cholesterol was also seen in patients who had prior episodes of
aggression (Buydens-Branchey et al. 2000).
The co-incidence of low serum cholesterol and occurrence of mixed manic
episodes has also been reported by Cassidy and Carroll (2002). In a study of 174
subjects, patients suffering from bipolar disorder and mixed manic episodes were
observed to have serum total cholesterol levels well below the reported national
average values. Cholesterol levels were also lower in patients who suffered from pure
manic disorders but a pronounced difference in levels of cholesterol was seen in
patients who suffered from bipolar disorder. Although it is unclear from this study
whether low cholesterol is the trigger for mixed manic episodes or whether the manic
episode results in lowered cholesterol levels, the study suggests a link between these
two health parameters (Cassidy and Carroll 2002).
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Low levels of serum cholesterol have been seen in patients in whom
Alzheimer’s disease (AD) has been diagnosed. In a study with 138 patients with a
confirmed diagnosis of Alzheimer’s disease, serum cholesterol levels were found to be
lower than normal people of similar average age. Within the AD cohort, the decrease
in cholesterol levels correlated with increasing levels of dementia (Tully et al. 2003).
Kim and colleagues, in a South Korean study of 291 individuals from a community as
well as 79 AD patients, reported that people with AD showed lower levels of serum
cholesterol. However, these researchers found no association between progressive
dementia and reduction in level of serum cholesterol (Kim et al. 2002). The authors
suggest that presence of lower serum cholesterol in AD patients may be a marker of
the impaired cognitive state rather than a causative agent.
The molecular mechanisms that result in lowered serum cholesterol, however,
appear to be different than just simple reduction in the synthesis of cholesterol
resulting from aging. This is indicated by studies which show that treatment with statin
drugs (HMGCoA reductase inhibitors) actually reduces the production of the amyloid
peptide (deposition of this peptide in plaques on neurons is the primary cause of
pathology in AD) and may actually show a neuroprotective therapeutic effect
(Buxbaum et al. 2002; Friedhoff et al. 2001). Since a deliberate reduction in the total
synthesis of cholesterol is not likely to be the triggering factor for the development of
AD, there must be other transport related phenomena associated with cholesterol
metabolism and its delivery to neurons.

CHOLESTEROL AND AIDS

Hypocholesterolemia has been noted in patients seropositive for human
immunodeficiency virus (HIV). In a study of 94 patients, serum cholesterol and
triglyceride levels were assessed along with other parameters in patients who were
seropositive and seronegative for HIV (Shor-Posner et al. 1993). Shor-Posner and
colleagues found that patients with low total cholesterol (below 150 mg/dl) were
seropositive (indicating greater viral load and active virus multiplication in the system)
as compared to patients with higher total cholesterol levels who were seronegative,
though they were infected with HIV (Shor-Posner et al. 1993). Cholesterol may
therefore be required as part of an antiviral mechanism that might possibly slow down
virus progression, if not prevent infection.
In a recent study with HIV-positive patients, Miguez and colleagues have
reported a startling connection between cholesterol levels and HIV virulence (Miguez
et al. 2010). These researchers compared the cholesterol levels of 165 HIV-positive
people at the beginning of highly active antiretroviral therapy (HAART) and after 24
weeks. Patients were classified as hypocholesterolemic if their total serum cholesterol
levels were below 150 mg/dl. These patients showed detectable viral loads as compared
to patients who had higher levels of serum cholesterol. The CD4+ cell counts in the
hypocholesterolemic patients were lower than those with higher cholesterol levels
implying that the immune response was modulated by hypocholesterolemia. The viral
load in hypocholesterolemic patients was seen despite HAART, indicating that
cholesterol may be included as a therapeutic molecule in such patients. Thymic output
was reduced in patients with low cholesterol levels resulting in very low (<200) CD4+cell counts in these patients.
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CONCLUSION
Cholesterol is an important molecule in human physiology and plays an
important role in all processes wherein cellular membrane composition and topography
are crucial. Cholesterol is both synthesized in the human body and is acquired from
food sources. Excess intake of dietary cholesterol resulting in excessive accumulation
of LDL-cholesterol in the vascular system has been identified as the causative factor
for cardiovascular disease (Daniels et al. 2009; Ferrieres 2009), leading to the
perception that keeping cholesterol levels low has to be a priority in health and
wellness management. However, exceedingly low levels of cholesterol also have other
detrimental effects on human physiology. Cholesterol is an important modulator of
neurotransmitter receptors like serotonin, which are involved in maintaining a healthy
neurophysiological state (Paila et al. 2008; Pucadyil et al. 2005). Cholesterol in the
form of lipoproteins also helps to fight bacterial infections by neutralizing bacterial
toxins and LPS, a function that may be severely compromised in hypocholesterolemic
patients suffering from sepsis (Wilson et al. 2003).
Cholesterol is certainly involved in the etiology of cardiovascular disease. LDLbound cholesterol is capable of acting as the seed molecule for the formation of
atherogenic plaques and can be a significant health hazard, moderate to extreme
reductions in the levels of total serum cholesterol also represent health hazards.
Mechanisms that result in reduction of total serum cholesterol also seem to
have a bearing on the health outcomes. For example patients suffering from SLOS,
although lacking in inherent cholesterol synthesis, do not always suffer from
depression resulting from serotonergic neuronal dysfunction. Many physiological
deficiencies of the SLOS defect can be overcome with dietary intake of cholesterol.
However, in other situations like sepsis and critical injury or surgical trauma,
cholesterol synthesis alone may not bring up the serum cholesterol to optimal levels in
some patients (Vyroubal et al. 2008; Wilson et al. 2003).
Cholesterol is perhaps a unique membrane component that is involved in
possibly every membrane turnover event such as exocyotosis and secretion (GondreLewis et al. 2006), neurotransmitter modulation (Paila et al. 2008; Pucadyil et al. 2005)
and endocytosis (Sabharanjak and Mayor 2004; Sabharanjak et al. 2002), viral
metabolism and cardiovascular health (Miguez et al. 2010).
Research suggests that management of ‘optimal’ cholesterol levels should be the
choice to make rather than aiming for very low levels of cholesterol in circulation.
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